Surrozen, Inc./DE Restructuring Charges
Surrozen, Inc./DE (SRZN) reported Restructuring Charges of $2.75 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-03-31
- Surrozen, Inc./DE restructuring charges for the quarter ending 2023-12-31 was $1.15M.
- Surrozen, Inc./DE restructuring charges for the quarter ending 2023-09-30 was $1.50M.
- Surrozen, Inc./DE restructuring charges for the quarter ending 2023-06-30 was $0.00.
- Surrozen, Inc./DE restructuring charges for the quarter ending 2023-03-31 was $1.20M.
- Surrozen, Inc./DE restructuring charges for fiscal 2023 was $2.75M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.66M derived: sum of 2 quarters · filed 2025-03-31 | $2.66M derived: sum of 3 quarters · filed 2025-03-31 | $2.75M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.50M 10-Q · filed 2024-11-06 | $1.50M derived: sum of 2 quarters · filed 2024-11-06 | $1.60M 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-K 3 month · filed 2023-08-09 | $1.20M 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $1.20M 10-K · filed 2025-03-31 | $1.21M 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |